SMS PHARMACEUTICALS LTD — SMSPHARMA | BSE: 532815

Strengths Strong FY26 growth: Revenue from operations increased 13.3% YoY to ₹886.9 Cr in FY26. Improving profitability: FY26 PAT rose about 48% to ₹102 Cr, while EBITDA increased around 23%, with EBITDA margin reaching about 20%. API-focused business: The company has capabilities in APIs and niche molecules, including large-volume molecules and Triptans. 🟠 Weaknesses API business concentration: Dependence on pharmaceutical API demand and pricing can create earnings volatility. Regulatory dependence: A significant part of the business requires continued compliance with USFDA and other international regulatory standards. Capex requirement: Capacity expansion and R&D investment require continuous capital allocation. Product/customer concentration risk: Performance can be affected if key molecules, customers or geographies experience pricing pressure or demand weakness. 🔵 Opportunities Capacity expansion: The company has been pursuing additional capacity and backward-integration projects. R&D expansion: Increased R&D investment can support development of higher-value APIs and new products. Export opportunity: Regulatory approvals can provide access to additional international markets. Specialty/niche APIs: Focus on niche molecules can potentially provide better margins than commoditised APIs. 🔴 Threats USFDA/regulatory risk: Future observations, warning letters or compliance issues could affect exports and manufacturing. API price erosion: Competition from Indian and Chinese manufacturers can pressure selling prices and margins. Raw-material volatility: Changes in input costs can affect profitability. Currency risk: A meaningful export business exposes the company to foreign-exchange movements. Pharma competition: Increasing competition in generic APIs can reduce pricing power.